Novartis division Alcon has introduced enhanced WaveLight refractive suite to optimize the patient and surgeon LASIK experience.
The software and hardware enhancements to the WaveLight refractive suite are designed to offer surgeons and patients a more comfortable and efficient LASIK experience.
The new platform provides a modernized user interface and extended equipment color options apart from offering a total and quick refractive procedure in the US.
Alcon North America region president Sergio Duplan said: “Although the WaveLight Refractive Suite is the market leader used in 65% of LASIK procedures performed in the US, we continued innovating to take the surgical experience to the next level.
“We’re confident these innovations will further optimize how surgeons use the Suite, arming them with the technology they need to address their patients’ vision correction needs.”
Alcon claims that the updates will redefine how surgeons utilize the WaveLight refractive suite incarrying out procedures with Contoura Vision, the first and only topography-guided LASIK treatment.
The suite enhancements integrate with Contoura Vision, offering surgeons true topography guidance and the ability to map the corneal features and imperfections of each eye using 22,000 data points from the WaveLight Topolyzer VARIO.
A clinical trial showed that 92.6% of eyes treated with Contoura Vision achieved 20/20 vision or better.
The software updates also improve the graphical user interface (GUI) of the Suite’s WaveNet Planning Station, EX500 Excimer Laser and the FS200 Femtosecond Laser.
The treatment will then be programmed for implementation by the advanced laser system of the WaveLight technology.
TLC Laser Eye Centers surgeon and national medical director Louis Probst said: “The enhancements to the WaveLight Refractive Suite are a welcome upgrade to an already robust platform, and the transition from the previous software was seamless.
“My surgery process is now more deliberate and streamlined because I’m able to clearly see and follow a logical flow of parameters on the redesigned interface.”
Earlier this year, it was revealed that Novartis is planning to spin off its eye care division Alcon into a standalone company, which will enable the two companies to focus on their respective growth strategies.